Obesity is the most prevalent chronic disease worldwide, affecting millions. Treatments that achieve meaningful weight reduction may improve clinical outcomes in individuals living with obesity. Disclaimer: This information is intended for Health Care Professionals only. This content is approved by Eli Lilly and company (“Lilly”). This content is i

Eli Lilly invites you to an exclusive webinar on Gulf Case Connect Tackling the Cardiometabolic Continuum Obesity is a multifactorial chronic disease influenced by genetic, environmental, physiological, and psychosocial factors, and it serves as a gateway to several noncommunicable diseases. It is recognized by the WHO as a chronic complex disease,

Introduction (1): Proton pump inhibitors (PPIs) are commonly used for acid-related disorders. PPIs have a strong inhibitory effect on gastric acid secretion and can be responsible for causing decreased nutrient absorption, changes to the gut microbiota, intestinal infections, and hypergastrinemia. Vonoprazan is a potassium-competitive acid blocker

Introduction: Hypercontractile esophagus (HE) is a rare esophageal motility disorder characterized by multipeaked peristaltic contractions of the esophagus (1). Although its etiology remains unclear, a potential association between acid reflux and HE has been suggested (1). The following case describes the use of vonoprazan, a potassium-competitive

Eli Lilly invites you to an expert-led webinar A New Start in Obesity Care: Clinical Insights on Join leading experts in this webinar as they explore the evolving landscape of obesity management and introduce Foundayo, the first and only oral GLP-1 receptor agonist approved for chronic weight management. Session Insights at a Glance: ➤ Obesity as a

Emerging prescribing trends in obesity management reflect growing interest in oral therapeutic options, driven by patient preference for non-injectable treatments and advancements in drug development. The availability of newer oral agents with improved efficacy profiles is influencing clinician adoption, particularly in patients seeking convenient

Eli Lilly invites you to an exclusive webinar on Reshaping Obesity: From Weight Management to Modern Obesity Care Approach To explore the evolving paradigm of obesity management, shifting beyond weight-centric approaches to a comprehensive, complication-focused care model, and to evaluate the role of advanced therapies such as Tirzepatide in achiev

Introduction: Dental erosion is the progressive and irreversible loss of tooth structure due to exposure to non-bacterial acids (1). Its prevalence is increasing worldwide, affecting approximately 30–45% of adults, and often results in functional impairment, aesthetic concerns, and complex restorative challenges if not addressed early (1). Managing

Eli Lilly invites you to an exclusive webinar on Obesity Compass Series | Empowering Obesity & OSA Care Healthcare professionals will gain insights into the evolving landscape of chronic metabolic disease management, with a focus on disease progression, clinical burden, and the impact of timely, effective interventions on patient-centred outcomes.